244 related articles for article (PubMed ID: 26982434)
21. Challenges in estimating the impact of pneumococcal conjugate vaccines through surveillance.
Vergison A; Hanquet G
Pediatr Infect Dis J; 2012 Apr; 31(4):400-3. PubMed ID: 22418653
[No Abstract] [Full Text] [Related]
22. Capsules, clones, and curious events: pneumococcus under fire from polysaccharide conjugate vaccine.
Long SS
Clin Infect Dis; 2005 Jul; 41(1):30-4. PubMed ID: 15937759
[No Abstract] [Full Text] [Related]
23. Cost-effectiveness of pneumococcal conjugate vaccination in Georgia.
Komakhidze T; Hoestlandt C; Dolakidze T; Shakhnazarova M; Chlikadze R; Kopaleishvili N; Goginashvili K; Kherkheulidze M; Clark AD; Blau J
Vaccine; 2015 May; 33 Suppl 1():A219-26. PubMed ID: 25919165
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.
Vučina VV; Filipović SK; Kožnjak N; Stamenić V; Clark AD; Mounaud B; Blau J; Hoestlandt C; Kaić B
Vaccine; 2015 May; 33 Suppl 1():A209-18. PubMed ID: 25919163
[TBL] [Abstract][Full Text] [Related]
25. Antibiotic resistance in Latin America: a cause for alarm.
Valenzuela MT; de Quadros C
Vaccine; 2009 Aug; 27 Suppl 3():C25-8. PubMed ID: 19540634
[TBL] [Abstract][Full Text] [Related]
26. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines.
Isaacman DJ; McIntosh ED; Reinert RR
Int J Infect Dis; 2010 Mar; 14(3):e197-209. PubMed ID: 19700359
[TBL] [Abstract][Full Text] [Related]
27. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
[TBL] [Abstract][Full Text] [Related]
28. What is the heterogeneity in the impact seen with pneumococcal conjugate vaccines telling us?
Hausdorff WP; Black S
Vaccine; 2017 Jul; 35(31):3797-3800. PubMed ID: 28619234
[TBL] [Abstract][Full Text] [Related]
29. Impact of conjugate 7-valent vaccination in Belgium: addressing methodological challenges.
Hanquet G; Lernout T; Vergison A; Verhaegen J; Kissling E; Tuerlinckx D; Malfroot A; Swennen B; Sabbe M;
Vaccine; 2011 Apr; 29(16):2856-64. PubMed ID: 21342667
[TBL] [Abstract][Full Text] [Related]
30. Letter from the Editor: pneumococcal conjugate vaccine.
Ellis R
Hum Vaccin Immunother; 2014; 10(9):2754. PubMed ID: 25483629
[No Abstract] [Full Text] [Related]
31. Progress in the introduction of rotavirus vaccine--Latin America and the Caribbean, 2006-2010.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2011 Dec; 60(47):1611-4. PubMed ID: 22129995
[TBL] [Abstract][Full Text] [Related]
32. Effect of pneumococcal conjugate vaccines on invasive pneumococcal disease.
Camargos P; Drumond E; Nascimento-Carvalho CM
Lancet Infect Dis; 2021 Apr; 21(4):453. PubMed ID: 33773123
[No Abstract] [Full Text] [Related]
33. Lessons learnt after the introduction of the seven valent-pneumococcal conjugate vaccine toward broader spectrum conjugate vaccines.
Falup-Pecurariu O
Biomed J; 2012; 35(6):450-6. PubMed ID: 23442357
[TBL] [Abstract][Full Text] [Related]
34. Prevention of pneumococcal disease in children. Pneumococcal conjugate vaccines: their use globally could have a major impact on public health.
Kyaw MH; Jones IG; Campbell H
Acta Paediatr; 2001 May; 90(5):473-6. PubMed ID: 11430703
[TBL] [Abstract][Full Text] [Related]
35. Pneumococcal conjugate vaccine: economic issues of the introduction of a new childhood vaccine.
Ray GT
Expert Rev Vaccines; 2002 Jun; 1(1):65-74. PubMed ID: 12908513
[TBL] [Abstract][Full Text] [Related]
36. A 10-valent conjugate vaccine for some countries.
Prescrire Int; 2011 Jan; 20(112):8. PubMed ID: 21462783
[No Abstract] [Full Text] [Related]
37. Declines in Pneumonia Mortality Following the Introduction of Pneumococcal Conjugate Vaccines in Latin American and Caribbean Countries.
de Oliveira LH; Shioda K; Valenzuela MT; Janusz CB; Rearte A; Sbarra AN; Warren JL; Toscano CM; Weinberger DM;
Clin Infect Dis; 2021 Jul; 73(2):306-313. PubMed ID: 32448889
[TBL] [Abstract][Full Text] [Related]
38. Effect of pneumococcal conjugate vaccines on invasive pneumococcal disease - Authors' reply.
de Cunto Brandileone MC; Castañeda-Orjuela C; Almeida SCG; Andrade AL
Lancet Infect Dis; 2021 Apr; 21(4):453-454. PubMed ID: 33773124
[No Abstract] [Full Text] [Related]
39. Pneumococcal conjugate vaccines. A review.
Galiza EP; Heath PT
Minerva Med; 2007 Apr; 98(2):131-43. PubMed ID: 17519855
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine.
Miller E; Andrews NJ; Waight PA; Slack MP; George RC
Vaccine; 2011 Nov; 29(49):9127-31. PubMed ID: 21983361
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
